We are excited to announce our participation in the 2025 American Society of Clinical Oncology Gastrointestinal Cancers symposium (ASCO GI) taking place January 23-25 in San Francisco, CA. Join us at the Quest Diagnostics table #91 to discover how our ultrasensitive minimal residual disease (MRD) testing is empowering oncologists with the insights needed to make confident treatment decisions for patients with GI cancers.
Advancing precision oncology
From residual disease detection and therapy monitoring to recurrence surveillance, Haystack MRD’s advanced ctDNA detection technology sees through the noise to deliver the precision needed to:
- Detect residual disease earlier than traditional methods
- Monitor recurrence with exceptional accuracy
- Tailor treatment strategies to help improve patient outcomes
Why visit Haystack MRD at ASCO GI?
- Speak with our experts about how our MRD test integrates seamlessly into your clinical practice
- Learn about real-world data and case studies showcasing Haystack MRD’s impact on GI cancer care
- Learn how Haystack MRD can support your research or drug development pipeline goals
